Teva Pharmaceutical Industries (NYSE:TEVA) reported a decline in third quarter earnings today.
Profits fell to $916 million, or $1.03 per share, from $1.05 billion, or $1.15 per share, in last year's third quarter.
Adjusted earnings of $1.25 per share were ahead of analyst expectations.
Net sales rose 2%, to $4.34 billion, shy of expectations.
Teva is looking for a stronger fourth quarter, which will include the launch of a generic version of Eli Lilly's (NYSE:LLY) schizophrenia drug Zyprexa.
Also today, medical technology company Becton Dickinson (NYSE:BDX) reported fiscal fourth quarter earnings of $300 million, or $1.36 per share, compared to $396.7 million, or $1.68 per share, in last year's fourth quarter.
Adjusted earnings of $1.39 per share fell short of analyst forecasts, while a 9.5% increase in revenue, to $2.05 billion, met expectations.
Becton Dickinson said it expects earnings of $5.75 to $5.85 per share in the 2012 fiscal year. It also plans to buyback $1.5 billion in common stock throughout the year.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.